| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 02/02/2005 | CN1575273A 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor antagonists |
| 02/02/2005 | CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/02/2005 | CN1575177A Cxcr3 antagonists |
| 02/02/2005 | CN1575176A Process for making substituted pyrazoles |
| 02/02/2005 | CN1575173A Macrolides containing pharmaceutical compositions |
| 02/02/2005 | CN1572792A Pyrazolo [4, 3-d] pyrimidine derivatives |
| 02/02/2005 | CN1572325A Treatment of lupus nephritis with anti-CD40L compounds |
| 02/02/2005 | CN1572320A Method for erythropoietin administration using pharmacokinetic and pharmacodynamic modeling |
| 02/02/2005 | CN1572299A Agents for improving excretory potency of urinary bladder |
| 02/02/2005 | CN1187370C Connective tissue growth factor fragments and methods and uses thereof |
| 02/02/2005 | CN1187369C Method for producing peptide salts. their use, and pharmaceutical prepns. containing these peptide salts |
| 02/02/2005 | CN1187358C Tetrahydro-heterocyclozaepinyl pyrimidine derivatives |
| 02/02/2005 | CN1187354C Adenosine receptor antagonists and methods of making and using the same |
| 02/02/2005 | CN1187342C Substituted 1-aminoalkyl-lactams compound and their use as muscarinic receptor antagonists |
| 02/02/2005 | CN1187330C Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 02/02/2005 | CN1187326C Novel compounds |
| 02/02/2005 | CN1187318C Solid composition suitable for oral administration comprising non hydroscopic salts of L-carnitine or alkanoyl-L-carnitine with 2-aminoethanesulfonic acid |
| 02/02/2005 | CN1187084C Use of alpha1 & beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease |
| 02/02/2005 | CN1187083C Method for producing Huafenliuwei pill |
| 02/02/2005 | CN1187046C Ketonic acid preparation for treating nephrosis |
| 02/01/2005 | US6849739 N-heterocyclic derivatives as NOS inhibitors |
| 02/01/2005 | US6849663 Particularly septic shock |
| 02/01/2005 | US6849653 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 02/01/2005 | US6849635 Sulfonamides |
| 02/01/2005 | US6849631 Semicarbazides and their uses |
| 02/01/2005 | US6849625 Use in manufacture of a medicament for use as an anti-invasive agent in containment and/or treatment of solid tumor disease |
| 02/01/2005 | US6849624 Headaches; antiarthritic agents; respiratory system disorders; psychological disorders |
| 02/01/2005 | US6849601 A conotoxin proteins is adrenergic blocking agents, treating disorders of urinary or cardiovascular conditions, having alpha 1-adrenoceptor antagonist activity |
| 02/01/2005 | US6849421 Nucleotide sequences coding enzymatic polypeptide for the use in the treatment of nervous system disorders |
| 01/27/2005 | WO2005007646A1 Substituted heterocyclic diarylamine analogues |
| 01/27/2005 | WO2005007645A1 Substituted 4-amino-1-benzylpiperidine compounds |
| 01/27/2005 | WO2005007644A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 01/27/2005 | WO2005007191A1 Medicinal composition |
| 01/27/2005 | WO2005007155A1 Medicinal composition |
| 01/27/2005 | WO2004073584A3 Cystitis treatment with high dose chondroitin sulfate |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | US20050020691 Pharmaceutical preparations comprising substituted beta-aminoalcohols |
| 01/27/2005 | US20050020661 Antidiabetic agents |
| 01/27/2005 | US20050020660 For example, 3-(3-methoxy-1-azabicyclo[2.2.2]oct-3-yl)-1,1-diphenyl-2-propyn-1-ol, 3-[(3R)-3-methoxy-1-azabicyclo [2.2.2]oct-3-yl]-1,1-diphenyl-2-propyn-1-ol; particularly suited for treating urinary incontinence |
| 01/27/2005 | US20050020656 L-histidine, D-histidine, DL-histidine, and/or salts thereof, and optionally cysteine, and/or cystine or salts; fibrosis may be of the kidney, pancreas, lung, vascular vessels, skin, bone marrow, or liver; may be given in foods or beverages |
| 01/27/2005 | US20050020609 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 01/27/2005 | US20050020604 5-HT receptor ligands and uses thereof |
| 01/27/2005 | US20050020602 Bone disorders; reduction concentration of parathyroid hormone in blood |
| 01/27/2005 | US20050020583 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2005 | US20050020573 5HT2c receptor modulators |
| 01/27/2005 | US20050020562 Drugs; analgesics; anesthetics; antiarrhythmia agents; antiinflammatory agents ; incontinence; gastrointestinal disorders; neurodegenerative disease |
| 01/27/2005 | US20050020541 Moderate neurotransmitters |
| 01/27/2005 | US20050020540 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050019908 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 01/27/2005 | US20050019872 PC-LECTIN protein; vaccines and diagnostic marker for prostate cancer |
| 01/27/2005 | US20050019858 Novel human cytokine/steroid receptor protein |
| 01/27/2005 | US20050019437 Administering a photoestrogen for treating urinary bladder infection and dry vagina; plant extracts is obtained from solvent extraction |
| 01/27/2005 | US20050019367 Continuous release of luteinizing hormone releasing hormone (lh-rh) analogue of leuprorelin, buserelin, triptorelin, and/or goserelin |
| 01/27/2005 | CA2532806A1 Medicinal composition |
| 01/27/2005 | CA2532805A1 Pharmaceutical composition |
| 01/27/2005 | CA2531401A1 Substituted heterocyclic diarylamine analogues |
| 01/27/2005 | CA2529790A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 01/26/2005 | EP1500658A1 Novel thiol derivative, process for producing the same and use thereof |
| 01/26/2005 | EP1500657A1 Substituted pyrazoles as P38 kinase inhibitors |
| 01/26/2005 | EP1500643A1 Benzamide derivatives |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500397A1 Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases |
| 01/26/2005 | EP1500396A1 Reboxetine for treating migraine headaches |
| 01/26/2005 | EP1500395A1 Reboxetine for treating fibromyalgia and other somatoform disorders |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499631A2 Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) |
| 01/26/2005 | EP1499619A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof |
| 01/26/2005 | EP1499613A1 Thioxanthine derivatives as myeloperoxidase inhibitors |
| 01/26/2005 | EP1499605A2 NF-KappaB INHIBITORS |
| 01/26/2005 | EP1499600A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 01/26/2005 | EP1499577A1 2-(2,6-dichlorophenyl)-diarylimidazoles |
| 01/26/2005 | EP1499352A1 Recombinant anti-interleukin-9 antibodies |
| 01/26/2005 | EP1499336A2 Protease inhibitors |
| 01/26/2005 | EP1499322A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy |
| 01/26/2005 | EP1499320A1 Novel compounds |
| 01/26/2005 | EP1499309A1 Prevention and treatment of functional somatic disorders, including stress-related disorders |
| 01/26/2005 | EP1499308A2 Tri-substituted heteroaryls and methods of making and using the same |
| 01/26/2005 | EP1499186A1 Use of heme oxygenase-1 and products of heme degradation |
| 01/26/2005 | EP1296976B1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 01/26/2005 | EP1278749B1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/26/2005 | EP1239867B1 Methods for treating and preventing damage to mucosal tissue |
| 01/26/2005 | EP1084109B1 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors |
| 01/26/2005 | EP0983267B1 Amidoaromatic ring sulfonamide hydroxamic acid compounds |
| 01/26/2005 | EP0944592B1 Vitamin d3 derivatives |
| 01/26/2005 | EP0866691B2 Sublingual and buccal administration of selegiline |
| 01/26/2005 | CN1571794A Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 01/26/2005 | CN1571789A Himbacine analogues as thrombin receptor antagonists |
| 01/26/2005 | CN1571787A Quinuclidine derivatives processes for preparing them and their uses as M2 and/or M3 muscarinic receptor inhibitors |
| 01/26/2005 | CN1571782A Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/26/2005 | CN1571781A 4-imidazolin-2-one compounds |
| 01/26/2005 | CN1571770A Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same |
| 01/26/2005 | CN1571680A PACAP compositions and methods for tumor imaging and therapy |
| 01/26/2005 | CN1571674A Use of histamine to treat liver disease |
| 01/26/2005 | CN1571672A Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 01/26/2005 | CN1571668A Salts formed of an AT1-receptor antagonist and a cardiovascular agent |
| 01/26/2005 | CN1569867A Preparation method and use of skunk bush extract morroniside |
| 01/26/2005 | CN1569191A 'Liuwei Dihuang' oral disintegrating tablet and its preparation |
| 01/26/2005 | CN1569178A Chinese medicine oral preparation for treating gynecologic inflammation and its preparation method |
| 01/26/2005 | CN1569166A Dispersible tablet of Chinese medicine for treating prostate disease and its preparation method |